Login
Super Investors TCG Crossover Management, LLC
TC

TCG Crossover Management, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$3.54B
Positions
57
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (20 quarters reported)

$4.16B $214M
Q4 21 Q4 22 Q4 23 Q4 24 Q4 25 Q3 26

$214M in Q4 2021 → $3.54B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
AS Abivax Sa American Depositary Shares 10.2% Trimmed 39% 3,663,038 $363M
Cg Oncology Inc 7.4% Unchanged 3,670,206 $260M
Amylyx Pharmaceuticals Inc 5.1% Unchanged 6,243,812 $182M
Spyre Therapeutics Inc 4.8% Unchanged 1,900,582 $169M
Tango Therapeutics Inc 4.8% Trimmed 25% 6,773,043 $169M
ZL Zai Lab Ltd-adr 4.6% Added 1.5% 6,229,081 $164M
Immunovant Inc 4.3% Unchanged 4,457,988 $151M
Dianthus Therapeutics Inc 4.2% Unchanged 1,676,624 $148M
Korsana Biosciences Inc 4.1% New 4,549,587 $146M
Kodiak Sciences Inc 3.9% Unchanged 1,445,538 $137M
Vor Biopharma Inc 3.1% Unchanged 5,673,078 $108M
First Tracks Biotherapeutics 2.9% Unchanged 2,895,304 $103M
Mirum Pharmaceuticals Inc 2.7% Added 5.4% 1,118,967 $95.6M
Biocryst Pharmaceuticals Inc 2.6% Unchanged 11,020,968 $91.8M
Disc Medicine Inc 2.5% Unchanged 1,341,862 $87.8M
Adarx Pharmaceuticals Inc 2.3% New 4,116,452 $82.1M
Cogent Biosciences Inc 2.3% Trimmed 49% 2,500,003 $80.1M
Tyra Biosciences Inc 2.1% Added 7.0% 3,475,980 $76M
Dyne Therapeutics Inc 2.1% Unchanged 4,615,144 $74.3M
Relay Therapeutics Inc 1.9% Trimmed 11% 3,783,529 $68.3M
Aura Biosciences Inc 1.8% Added 6.6% 10,165,357 $63.8M
Savara Inc 1.8% Unchanged 12,362,205 $63.8M
Xencor Inc 1.4% Trimmed 16% 2,055,938 $51.3M
Avalo Therapeutics Inc 1.3% Unchanged 3,017,120 $46.3M
Monte Rosa Therapeutics Inc 1.3% Trimmed 18% 3,781,532 $45.1M
Mbx Biosciences Inc 1.1% Unchanged 650,000 $38.1M
Entera Bio Ltd 1.0% New 12,254,901 $35.7M
Janux Therapeutics Inc 0.9% Unchanged 1,789,617 $30.9M
Tarsus Pharmaceuticals Inc 0.9% New 388,164 $30.5M
Century Therapeutics Inc 0.9% Unchanged 17,754,430 $30.4M
Obsidian Therapeutics Inc 0.9% New 2,196,138 $30.2M
PB Pharvaris Bv 0.8% Trimmed 6.0% 947,544 $30.1M
Lb Pharmaceuticals Inc 0.8% Trimmed 47% 765,050 $29.4M
Editas Medicine Inc 0.8% Unchanged 11,111,111 $28.6M
Tectonic Therapeutic Inc 0.8% Unchanged 1,204,891 $28.1M
Inflarx N V 0.7% Unchanged 14,500,000 $26.1M
Perspective Therapeutics Inc 0.6% Unchanged 7,915,567 $21.8M
Agomab Therapeutics Nv 0.6% Trimmed 11% 1,820,831 $20.2M
Silence Therapeutics PLC 0.6% Trimmed 40% 1,819,035 $19.9M
Alector Inc 0.5% Unchanged 10,000,000 $18.5M
Biohaven Ltd 0.5% Trimmed 29% 1,262,423 $16.9M
Monopar Therapeutics Inc 0.5% Trimmed 0.5% 202,242 $16.1M
Adc Therapeutics Sa 0.4% Unchanged 11,390,175 $13.9M
Entrada Therapeutics Inc 0.2% Unchanged 1,060,230 $6.73M
Cullinan Therapeutics Inc 0.2% Unchanged 406,786 $6.24M
Agenus Inc 0.2% New 603,892 $6M
Ocular Therapeutix Inc 0.2% Trimmed 56% 720,323 $5.52M
Arvinas Inc 0.2% Unchanged 707,098 $5.47M
Korro Bio Inc 0.1% Unchanged 416,301 $4.13M
RA Research Alliance Corp Iv-a 0.1% New 300,000 $3.6M
Alx Oncology Holdings Inc 0.1% Trimmed 56% 2,465,436 $3.43M
Aktis Oncology Inc 0.1% Trimmed 81% 133,457 $2.6M
Jatt Ii Acquisition Corp 0.1% Unchanged 200,000 $2.25M
Leonabio Inc 0.0% Unchanged 464,398 $1.66M
Jatt Iii Acquisition Corp 0.0% New 100,000 $1.1M
Context Therapeutics Inc 0.0% Unchanged 2,682,696 $806K
Eikon Therapeutics Inc 0.0% Unchanged 37,902 $305K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa American Depositary Shares Trimmed −2,344,796 −$232M 10.2%
Korsana Biosciences Inc New +4,549,587 +$146M 4.1%
Adarx Pharmaceuticals Inc New +4,116,452 +$82.1M 2.3%
Cogent Biosciences Inc Trimmed −2,354,433 −$75.4M 2.3%
Revolution Medicines Inc Exited −340,899 −$63.8M —
Tango Therapeutics Inc Trimmed −2,308,158 −$57.6M 4.8%
Surrozen Inc Exited −1,473,101 −$38.2M —
Entera Bio Ltd New +12,254,901 +$35.7M 1.0%
Tarsus Pharmaceuticals Inc New +388,164 +$30.5M 0.9%
Altimmune Inc Exited −10,000,000 −$30.4M —

Showing the 10 largest of 32 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Centessa Pharmaceuticals PLC Exited −4,286,480 −$170M —
ZL Zai Lab Ltd-adr New +6,137,627 +$117M 2.8%
Aura Biosciences Inc New +9,533,333 +$67.7M 1.6%
AS Abivax Sa American Depositary Shares Trimmed −473,251 −$63.1M 19.2%
First Tracks Biotherapeutics New +2,895,304 +$58.3M 1.4%
Tango Therapeutics Inc Trimmed −1,449,870 −$45.3M 6.8%
Revolution Medicines Inc Trimmed −235,574 −$44.1M 1.5%
Biohaven Ltd Trimmed −2,851,365 −$42.4M 0.6%
Avalo Therapeutics Inc Added +2,278,737 +$42.1M 1.3%
Fulcrum Therapeutics Inc Exited −5,250,000 −$40.3M —

Showing the 10 largest of 30 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Biocryst Pharmaceuticals Inc New +11,020,968 +$105M 3.0%
Vor Biopharma Inc New +5,673,078 +$96.5M 2.8%
Mirum Pharmaceuticals Inc Added +1,000,000 +$92.4M 2.8%
Rapt Therapeutics Inc Exited −2,582,408 −$87.5M —
Disc Medicine Inc New +1,341,862 +$85.8M 2.5%
AS Abivax Sa American Depositary Shares Trimmed −630,511 −$70.2M 20.6%
Immunovant Inc Added +2,797,055 +$69.5M 3.2%
Eyepoint Pharmaceuticals Inc Exited −3,572,335 −$65.3M —
LT Liquidia Technologies Inc Trimmed −1,307,036 −$49.3M 0.4%
Tango Therapeutics Inc Trimmed −2,231,023 −$46.7M 6.3%

Showing the 10 largest of 34 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Monte Rosa Therapeutics Inc New +4,622,151 +$72.5M 2.4%
Tourmaline Bio Inc Exited −1,311,783 −$62.7M —
Biohaven Ltd New +4,631,317 +$52.3M 1.7%
Immunovant Inc New +1,660,933 +$42.2M 1.4%
Tango Therapeutics Inc Added +4,225,898 +$37.4M 3.7%
Upstream Bio Inc Trimmed −1,373,217 −$37.3M 0.7%
Adc Therapeutics Sa Added +10,000,000 +$35.3M 1.3%
Cogent Biosciences Inc Trimmed −930,000 −$33M 6.9%
Rapt Therapeutics Inc Added +946,133 +$32M 2.9%
Disc Medicine Inc Exited −465,257 −$30.7M —

Showing the 10 largest of 29 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 17, 2025

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa American Depositary Shares Added +1,055,000 +$89.6M 29.7%
Cidara Therapeutics Inc Exited −1,005,901 −$49M —
LT Liquidia Technologies Inc New +1,710,084 +$38.9M 1.9%
Agios Pharmaceuticals Inc Added +733,038 +$29.4M 2.8%
Lb Pharmaceuticals Inc New +1,745,016 +$27.6M 1.4%
Revolution Medicines Inc New +436,473 +$20.4M 1.0%
Korro Bio Inc New +416,301 +$19.9M 1.0%
Tango Therapeutics Inc Trimmed −2,199,804 −$18.5M 3.5%
Spyre Therapeutics Inc New +1,100,582 +$18.4M 0.9%
Soleno Therapeutics Inc Exited −186,250 −$15.6M —

Showing the 10 largest of 32 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Mineralys Therapeutics Inc Exited −2,470,265 −$39.2M —
Agios Pharmaceuticals, Inc. New +697,003 +$23.2M 2.6%
Rapt Therapeutics, Inc. Exited −13,090,200 −$16M —
Rapt Therapeutics, Inc. New +1,636,275 +$13.1M 1.5%
Compass Pathways Ltd Exited −3,858,000 −$11M —
Dyne Therapeutics Inc Added +1,116,510 +$10.6M 4.1%
Enliven Therapeutics, Inc. New +498,000 +$9.99M 1.1%
Soleno Therapeutics Inc Trimmed −88,750 −$7.44M 1.8%
Nektar Therapeutics New +266,666 +$6.89M 0.8%
Aerovate Therapeutics Inc Exited −2,240,809 −$5.62M —

Showing the 10 largest of 14 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

Company Action Shares changed Value of change % of portfolio
Soleno Therapeutics Inc Trimmed −275,000 −$19.6M 2.7%
Tyra Biosciences Inc Added +909,000 +$8.45M 3.7%
Amylyx Pharmaceuticals Inc Added +1,300,000 +$4.6M 2.9%
Disc Medicine Inc Trimmed −21,700 −$1.08M 3.2%
Rapt Therapeutics, Inc. Trimmed −45,060 −$55K 2.2%
Keros Therapeutics Inc Trimmed −550,000 — —

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Edgewise Therapeutics, Inc. Exited −2,112,984 −$56.4M —
Upstream Bio Inc New +2,801,763 +$44.9M 4.4%
Tango Therapeutics Inc New +10,736,000 +$33.2M 3.2%
Dianthus Therapeutics Inc New +1,501,624 +$32.7M 3.2%
Cidara Therapeutics, Inc. New +1,005,901 +$26.1M 2.5%
Rapt Therapeutics, Inc. New +13,135,260 +$19.8M 1.9%
Eyepoint Pharmaceuticals Inc Added +2,650,000 +$19.7M 2.6%
Tarsus Pharmaceuticals, Inc. Exited −231,820 −$7.62M —
Keros Therapeutics Inc Trimmed −329,344 −$5.21M 0.9%
An2 Therapeutics, Inc. Exited −1,555,118 −$1.66M —

Showing the 10 largest of 14 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support